After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

A century ago, the strange behavior of atoms and elementary particles led physicists to formulate a new theory of nature. That theory, quantum mechanics, found immediate success, proving its worth ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Palantir's stock is up nearly 10 % month-to-date and has gone even higher year-to-date, as bullish sentiment surges ahead of its second quarter earnings. Tempus AI shares, currently at about $64, have ...

Looking to get into statistical programming but lack industry experience? We spoke with several statistical programmers from diverse backgrounds, and one thing became clear—there’s no single path to ...

Shares of early-stage biotech stocks, including Biohaven (NYSE: BHVN), Recursion Pharmaceuticals (NASDAQ: RXRX), and CRISPR Therapeutics (NASDAQ: CRSP), plunged in March, with the stocks down 35.3%, ...